Erasca, Inc. Stock Price, News & Analysis

Erasca (Nasdaq: ERAS) announced that the U.S. Patent and Trademark Office issued Patent No. 12,458,647, titled “Macrocyclic Derivative And Use Thereof,” covering the composition of matter for the pan‑RAS molecular glue ERAS-0015 and related compositions.

The patent provides protection through September 2043, subject to possible patent term adjustments or extensions. The company noted it in‑licensed the program in May 2024 and said initial Phase 1 monotherapy data for ERAS-0015 and for pan‑KRAS inhibitor ERAS-4001 are expected in 2026.

Erasca (Nasdaq: ERAS) announced management will participate in investor conferences and one-on-one meetings in November 2025. Events and times:

• Guggenheim 2nd Annual Healthcare Innovation Conference — Boston, Nov 10-12; Fireside chat on Nov 11 at 2:00 pm ET.
• Stifel 2025 Healthcare Conference — New York, Nov 11-13; Fireside chat on Nov 12 at 1:20 pm ET.
• Jefferies Global Healthcare Conference — London, Nov 17-20; Fireside chat on Nov 19 at 10:30 am GMT.

A live audio webcast will be available at Erasca.com/events, with archived replays accessible for 30 days after each webcast.

Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancer therapies, will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference. The company's management will deliver a presentation on Tuesday, September 9, 2025, at 3:20 PM ET at the Sheraton New York Times Square and engage in one-on-one investor meetings.

Investors can access a live audio webcast of the presentation through Erasca.com/events, with a replay available for 30 days following the event.

Erasca (Nasdaq: ERAS), a precision oncology company, reported significant progress in its RAS-targeting cancer therapy development program and Q2 2025 financial results. The company achieved key milestones with FDA clearance for two investigational new drug (IND) applications: ERAS-4001 (pan-KRAS inhibitor) and ERAS-0015 (pan-RAS molecular glue), both targeting RAS-mutant solid tumors.

The company maintains a strong financial position with $386.7 million in cash and equivalents as of June 30, 2025, expected to fund operations into H2 2028. Q2 2025 saw reduced losses with a net loss of $33.9 million ($0.12 per share), compared to $63.2 million ($0.29 per share) in Q2 2024. Initial Phase 1 monotherapy data for both drug candidates is expected in 2026.

Erasca announced FDA clearance of its IND application for ERAS-4001, a potential first-in-class and best-in-class pan-KRAS inhibitor for treating KRAS-mutant solid tumors. ERAS-4001 targets multiple KRAS mutations and wildtype KRAS while sparing HRAS and NRAS, potentially offering a better therapeutic window compared to pan-RAS inhibitors. The company also received IND clearance for ERAS-0015, a potential best-in-class pan-RAS molecular glue, both ahead of guidance. The BOREALIS-1 Phase 1 trial will evaluate ERAS-4001's safety, tolerability, and preliminary efficacy, while ERAS-0015 is being studied in the AURORAS-1 Phase 1 trial. Initial monotherapy data for both RAS-targeting programs is expected in 2026. The development addresses unmet needs for approximately 2.2 million people diagnosed annually worldwide with KRAS-mutant tumors.

Erasca (NASDAQ: ERAS), a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancer therapies, has announced its participation in two major investor conferences in June 2025:

1. Jefferies Global Healthcare Conference (June 3-5) in New York, featuring a fireside chat on June 4 at 5:30 PM ET

2. Goldman Sachs 46th Annual Global Healthcare Conference (June 9-11) in Miami Beach, with a fireside chat scheduled for June 10 at 2:40 PM ET

Management will participate in one-on-one investor meetings at both conferences. Live audio webcasts will be available at Erasca.com/events, with replays accessible for 30 days after each event.

Erasca (NASDAQ: ERAS) reported Q1 2025 financial results and business updates, highlighting progress in its RAS-targeting cancer therapy programs. The company announced FDA clearance for ERAS-0015 (pan-RAS molecular glue) and IND submission for ERAS-4001 (pan-KRAS inhibitor), with initial Phase 1 monotherapy data expected in 2026 for both programs. Financially, Erasca reported $411.1 million in cash as of March 31, 2025, extending their cash runway to H2 2028. Q1 2025 showed improved financial metrics with net loss decreasing to $31.0 million ($0.11 per share) compared to $35.0 million ($0.23 per share) in Q1 2024. R&D expenses decreased to $26.0 million from $28.6 million, while G&A expenses reduced to $9.7 million from $10.3 million year-over-year.

Erasca (NASDAQ: ERAS) announced significant advancements in its RAS-targeting cancer therapy programs. The FDA cleared the IND for ERAS-0015, a pan-RAS molecular glue, and the company submitted an IND for ERAS-4001, a potential first-in-class pan-KRAS inhibitor. Both developments occurred ahead of schedule, with Phase 1 monotherapy data expected in 2026. The company also announced a strategic decision to seek partnership opportunities for naporafenib, extending their cash runway guidance from H2 2027 to H2 2028. ERAS-0015 targets approximately 2.7 million patients annually with RAS-mutant tumors, while ERAS-4001 addresses over 2.2 million patients with KRAS-mutant tumors. This strategic prioritization allows Erasca to focus on advancing its RAS-targeting franchise while maintaining over three years of projected cash runway.

Erasca (NASDAQ: ERAS), a clinical-stage precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers, has announced its participation in the Bank of America Securities 2025 Health Care Conference. The event will take place at the Encore Hotel in Las Vegas, Nevada. The company's management will deliver a presentation on Wednesday, May 14, 2025, at 2:35 PM Pacific Time and will engage in one-on-one investor meetings. A live audio webcast will be accessible at Erasca.com/events, with a replay available for 30 days following the presentation.